Program Information

This non-CME symposium is not part of the ATC official educational program and the sessions and content are not endorsed by ATC.

Sunday, June 2, 2019
12:45 PM – 1:00 PM ET

Panel-Based Faculty Discussions
1:00 PM – 2:15 PM ET

Sheraton Boston Hotel
Constitution Ballroom, 2nd Level
39 Dalton Street
Boston, MA 02199

Join us for a spirited clinical case-based discussion amongst world-renowned experts. Ask your challenging questions about antibody-mediated rejection (AMR) in renal transplant patients and learn about emerging therapies for improved patient outcomes.


12:45 PM – 1:00 PM
Lunch and Registration
1:00 PM – 1:10 PM
Welcome and Introductions
Robert A. Montgomery, MD, DPhil, FACS
1:10 PM – 1:25 PM
Clinical Case 1:
Renal Transplant Patient with Difficult-to-Treat AMR
Robert A. Montgomery, MD, DPhil, FACS and Full Panel
1:25 PM – 1:30 PM
Audience Q&A
All Faculty
1:30 PM – 1:45 PM
Clinical Case 2:
Renal Transplant Patient with Chronic Active AMR
Stanley C. Jordan, MD and Full Panel
1:45 PM – 1:50 PM
Audience Q&A
All Faculty
1:50 PM – 2:05 PM
Clinical Case 3:
Renal Transplant Patient with Refractory AMR
Fritz Diekmann, MD and Full Panel
2:05 PM – 2:15 PM
Audience Q&A and Closing
All Faculty


Robert A. Montgomery, MD, DPhil, FACS (Chair)
Professor of Surgery
Director, NYU Langone Transplant Institute
New York, NY (USA)
Fritz Diekmann, MD
Chief, Kidney Transplant Unit
Associate Professor
Hospital Clinic de Barcelona
Barcelona, Spain (EUROPE)
Stanley C. Jordan, MD
Director, Division of Nephrology
Medical Director, Kidney Transplant Program
Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory
Cedars-Sinai Medical Center
Los Angeles, CA (USA)

After engaging in this activity, transplant clinicians will be able to:

  • Describe the pathophysiology of antibody-mediated rejection (AMR), including the significance of the activation of the complement system cytokine pathways, in order to effectively and aggressively institute treatment
  • Discuss existing and emerging treatment options for AMR, including anti-complement and anti-cytokine strategies
  • Select appropriate therapeutic agents and protocols to treat AMR and prolong allograft survival

Clinicians who manage antibody-mediated rejection (AMR) in patients who undergo solid organ transplant (SOT).

This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with Advancing Knowledge in Healthcare (AKH) Inc. All faculty and planner conflicts of interest were identified and resolved and AKH has reviewed the content and determined it to be fair, balanced, and without commercial bias.

This activity is supported by an independent educational grant from CSL Behring.

There is no fee for this educational activity.

Please contact Nicole Fortune at if you have any questions.

Facebook  Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found
at or by calling toll-free (866) 770-RMEI.